ERBB2 and breast cancer: The decrease in breast cancer mortality is the result of major therapeutic advances (hormone therapy, taxanes, and anti-Her2 targeted therapy) associated with an increase in the proportion of cancers diagnosed at an early stage, notably through organized screening.